BioNTech Buys a Plant to Manufacture Its Coronavirus Vaccine

BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) haven't even released phase 3 clinical trial data for their coronavirus vaccine, BNT162b2, but BioNTech is already preparing to ramp up production next year through the acquisition of a manufacturing plant from Novartis (NYSE: NVS). BioNTech and Novartis didn't disclose the financial terms of the transaction.

The manufacturing plant, which is located in Marburg, Germany, can produce up to 750 million doses per year. BioNTech plans to take ownership in the fourth quarter of 2020. It will take some time to convert the plant to producing BNT162b2.

Nevertheless, the biotech has an ambitious goal of having the plant up and running quickly enough so that the company can produce 250 million doses of BNT162b2 in the first half of 2021. BioNTech noted that the quick transition is possible since the plant has "well-established biotechnology drug substance and drug product manufacturing equipment as well as an experienced team."

A medical professional with gloved hands gives an injection into a person's shoulder.

Image source: Getty Images.

Given BioNTech's and Pfizer's manufacturing capacities, the companies have previously said they expect to be able to produce 100 million doses by the end of this year and 1.3 billion doses by the end of 2021. The vaccine is a two-dose regimen, so the actual number of patients who can be protected is half of the dose production.

Pfizer and BioNTech hope to have phase 3 clinical trial data next month that will show BNT162b2 protects participants from getting COVID-19, but the timing of the data release will ultimately be based on the rate of infection for the group that received placebo.

10 stocks we like better than BioNTech
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and BioNTech wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of August 1, 2020


Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More